In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Blood Glucose monitor reimbursement

This article was originally published in The Gray Sheet

Executive Summary

Health Care Financing Administration proposes to set special payment limits for standard home blood glucose monitors in a Jan. 6 Federal Register notice. HCFA says that current fee schedule amounts for the monitors "are grossly excessive and not inherently reasonable." The agency is proposing that payment be equal to either 80% of the lesser of the actual charge of the device or a special payment limit of $57 for the continental U.S. and $65 for Alaska, Hawaii, Puerto Rico and the Virgin Islands



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts